FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

@article{Thussbas2006FGFR4AA,
  title={FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.},
  author={C Thussbas and Jorg Nahrig and Sylvia Streit and Johannes Bange and R. Kates and Kurt Ulm and Martina Kiechle and Heinz Hoefler and Axel Ullrich and Nadia Harbeck},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={625}
}
625 Background: Bange et al. recently found that a single-nucleotide polymorphism (SNP) at codon 388 of fibroblast growth factor receptor 4 (FGFR4) gene, causing a transmembrane domain missense mutation (Gly388Arg), is associated with outcome in node-positive breast cancer. METHODS This study addresses clinical relevance of this SNP, FGFR4 genotype, phenotype, and HER2 regarding patient outcome and influence of adjuvant systemic therapy in a substantial primary breast cancer collective (n=372… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 64 extracted citations

Similar Papers

Loading similar papers…